Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Pregnancy Registry Guidance Should Stratify Drugs By Prevalence Of Use

This article was originally published in The Tan Sheet

Executive Summary

Stratification of drugs according to prevalence of use in women of childbearing age would assist industry in determining when pregnancy registries should be established, FDA's Reproductive Health Drugs Advisory Committee agreed at a meeting Oct. 18.

You may also be interested in...

Pregnancy Registry Recruitment Notices Should Be Cleared - FDA Guidance

Manufacturers will need to balance the "active recruitment" strategies for pregnancy registries urged by FDA with the agency's warning that recruitment efforts must not promote use in pregnant women, a draft guidance on pregnancy registries states.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts